BCL2 and acute myeloid leukemia: Venetoclax (VEN) was developed as a BH3 mimetic that selectively inhibits BCL2 and has demonstrated potential in various cancers, including breast cancer and colorectal cancer, as well as acute myeloid leukemia [82,83,84].